Waldemar Priebe, Ph.D.
Department of Experimental Therapeutics, Division of Cancer Medicine
About Dr. Priebe
Dr. Priebe’s research merges biology with chemistry and focuses on the design and development of drugs that selectively target DNA and inhibitors of signaling and metabolic pathways important to tumor progression and survival. He has a long term interest in the field of carbohydrates ranging from organic chemistry of carbohydrates to the exploitation of carbohydrate metabolism in normal cells and cancer cells.
Dr. Priebe is noted for his successful development of new therapeutic entities for the treatment of cancer. During his career, he has generated an extensive library of distinct, novel cancer-fighting compounds (numbering in the thousands) covering many structural scaffolds and diverse therapeutic areas. The invention of these agents has led to many patents and numerous licenses. Three of his drugs are in clinical trials and several others are in different stages of preclinical development.
In addition to his position at M. D. Anderson, Dr. Priebe holds the title of Professor of Chemistry in the Republic of Poland.
Dr. Priebe has published more than 200+ peer-reviewed journal articles and his work has led to over 40 patents. Additionally, he has organized at least 25 national and international conferences and been an invited lecturer on more than 150 occasions.
Present Title & Affiliation
Primary Appointment
Professor of Medicinal Chemistry, Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
The research in my laboratory focuses on novel approaches to rational drug design and preclinical translational research. The approach we use, "translational chemistry," involves the intersection of chemistry and biology, where we blend our expertise in cutting-edge synthetic organic chemistry and bio-organic chemistry with the biology of cancer and all aspects of drug discovery and development. The ultimate measure of our success is the translation of our research and discoveries at the bench into viable drugs for patients with cancer.
Education & Training
Degree-Granting Education
| 1978 | Institute of Organic Chemistry, Polish Academy of Sciences, Warsaw, POL, PHD, Organic Chemistry, Total Synthesis of Lincomycin Analogs |
| 1971 | University of Warsaw, Warsaw, POL, MS, Organic Chemistry |
Postgraduate Training
| 1979-1980 | Postdoctoral Fellowship, Ohio State University, Department of Chemistry, Columbus, OH |
Experience & Service
Consultantships
Scientific Advisory Board, Moleculin LLC (Scientific Advisory Board), Houston, TX, 2008 - Present
Honors & Awards
| 2015 | Member of National Development Council of Poland (Narodowa Rada Rozwoju), President of Poland |
| 2015 | Wybitny Polak (The Outstanding Polish Scientist Award- USA edition), Fundacjia Polskiego Godła Promocyjnego-Teraz Polska |
| 2013 | The Polish Academy of Sciences Medal, Polish Academy of Sciences |
| 2013 | Order of Polonia Restituta, Officer's Cross class, President of Poland |
| 2009 | Melville L. Wolfrom Award, American Chemical Society, Washington, DC |
| 2007 | S. Bineckiego Medal, Warsaw, Poland, for achievement in medicinal chemistry |
| 2005 | The Award of T. Sendzimir Medal, Association of Polish Inventors |
| 2004 | The official title of Professor from Aleksander Kwasniewski, President of the Republic of Poland. Priebe was honored in a ceremony held in Poland January 16, 2004 for his seminal contributions in the field of Chemistry |
| 2002 | Chairman Elect, Division of Carbohydrate Chemistry, American Chemical Society |
| 1999 | Honorary Membership of The Sociedad Argentina de Investigaciones en Quimica Organica (SAIQQ) |
| 1995 | The University of Texas Graduate School of Biomedical Sciences Deans Excellence Award |
| 1994 | Polish Chemical Society Maria Curie-Sklodowska Medal |
Selected Publications
Peer-Reviewed Articles
- Rios Perez MV, Roife D, Dai B, Pratt M, Dobrowolski R, Kang Y, Li X, Augustine JJ, Zielinski R, Priebe W, Fleming JB. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models. Surg Open Sci 1(2):Pages 56-63, 2019. e-Pub 2019. PMID: 33981979.
- Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of Brain Metastases: Prioritization of Therapeutic Targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
- Olbryt M, Rusin A, Fokt I, Habryka A, Tudrej P, Student S, Sochanik A, Zielinski R, Priebe W. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation. Invest New Drugs 35(5):545-555, 2017. e-Pub 2017. PMID: 28417283.
- Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W. Novel Molecular Multilevel Targeted Antitumor Agents. Cancer Transl Med 3(3):69-79, 2017. e-Pub 2017. PMID: 28825042.
- Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AG. MODELING STROMA-INDUCED DRUG RESISTANCE IN A TISSUE-ENGINEERED TUMOR MODEL OF EWING SARCOMA. Tissue Eng Part A 23(1-2):80-89, 2017. e-Pub 2016. PMID: 27923328.
- Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
- Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. J Transl Med 14(1):46, 2016. e-Pub 2016. PMID: 26861698.
- Priebe W. Obituary: Derek Horton (1933-2015). Glycoconj J 32(8):557-8, 2015. PMID: 26498188.
- Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H, Lang FF. Mesenchymal Stem Cells Isolated from Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 33(8):2400-15, 2015. e-Pub 2015. PMID: 25966666.
- Malinska M, Fokt I, Priebe W, Wozniak K,. Bromine Atom Interactions in Biologically Active Acrylamide Derivatives. Crystal Growth and Design 15(6):2632–2642, 2015.
- Mansilla S, Vizcaíno C, Rodríguez-Sánchez MA, Priebe W, Portugal J. Autophagy modulates the effects of bis-anthracycline WP631 on p53-deficient prostate cancer cells. J Cell Mol Med 19(4):786-798, 2015. e-Pub 2015. PMID: 25689150.
- Lee HT, Xue J, Chou PC, Zhou A, Yang P, Conrad CA, Aldape KD, Priebe W, Patterson C, Sawaya R, Xie K, Huang S. Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells. Oncotarget 6(12):10016-29, 2015. PMID: 25881542.
- Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB. Therapeutic targets in subependymoma. J Neuroimmunol 277(1-2):168-175, 2014. e-Pub 2014. PMID: 25465288.
- Kalinowska M, Bielawska A, Lewandowska-Siwkiewicz H, Priebe W, Lewandowski W. Apples: Content of phenolic compounds vs. variety, part of apple and cultivation model, extraction of phenolic compounds, biological properties. Plant Physiol Biochem 84C:169-188. e-Pub 2014. PMID: 25282014.
- Emmett MR, Kroes RA, Moskal JR, Conrad CA, Priebe W, Laezza F, Meyer-Baese A, Nilsson CL. Integrative Biological Analysis for Neuropsychopharmacology. Neuropsychopharmacology 39(1):5-23, 2014. e-Pub 2013. PMID: 23800968.
- Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, Giraud AS. Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo. PLoS One 9(5):e95993, 2014. e-Pub 2014. PMID: 24804649.
- Mielecki M, Krawiec K, Kiburu I, Grzelak K, Zagórski W, Kierdaszuk B, Kowa K, Fokt I, Szymanski S, Swierk P, Szeja W, Priebe W, Lesyng B, LaRonde-LeBlanc N. Development of novel molecular probes of the Rio1 atypical protein kinase. Biochim Biophys Acta 1834(7):1292-301, 2013. e-Pub 2013. PMID: 23523885.
- Fokt I, Skora S, Conrad C, Madden T, Emmett M, Priebe W. D-Glucose and D-mannose-based metabolic probes. Part 3: Synthesis of specifically deuterated D-glucose, D-mannose, and 2-deoxy-D-glucose. Carbohydr Res 368:111-9, 2013. e-Pub 2012. PMID: 23376241.
- Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O. Regulation of HGF expression by ?EGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 15(1):73-84, 2013. PMID: 23359207.
- Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, Aldape K, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol 14(9):1136-45, 2012. e-Pub 2012. PMID: 22753228.
- Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer 30(7):8-17, 2012. e-Pub 2011. PMID: 21792892.
- Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Grynkiewicz G, Lesyng B, Priebe W, Kaminska B. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells. Cancer Biol Ther 13(8):657-70, 2012. e-Pub 2012. PMID: 22555804.
- Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107(3):487-501, 2012. e-Pub 2012. PMID: 22249692.
- Nilsson CL, Dillon R, Devakumar A, Shi SD, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, Kaboord BJ, Sarracino D, Rezai T, Prakash A, Lopez M, Ji Y, Priebe W, Lang FF, Colman H, Conrad CA. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 9(1):430-43, 2010. PMID: 19899826.
- Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9(1):67-78, 2010. e-Pub 2010. PMID: 20053772.
- Fokt I, Szymanski S, Skora S, Cybulski M, Madden T, Priebe W. D-Glucose- and D-mannose-based antimetabolites. Part 2. Facile synthesis of 2-deoxy-2-halo-D-glucoses and -D-mannoses. Carbohydr Res 344(12):1464-1473, 2009. e-Pub 2009. PMID: 19625015.
- Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother 58(7):1023-32, 2009. e-Pub 2008. PMID: 19002459.
- Gao H, Priebe W, Glod J, Banerjee D. Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell-Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell-Conditioned Medium. Stem Cells 27(4):857-865, 2009. PMID: 19350687.
- Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228-35, 2008. PMID: 19088040.
- van Schalkwyk DA, Priebe W, Saliba KJ. The inhibitory effect of 2-halo derivatives of D-glucose on glycolysis and on the proliferation of the human malaria parasite Plasmodium falciparum. J Pharmacol Exp Ther 327(2):511-7, 2008. e-Pub 2008. PMID: 18713952.
- Heimberger AB, Priebe W. Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers. Recent Pat CNS Drug Discov 3(3):179-88, 2008. PMID: 18991807.
- Corvis Y, Korchowiec B, Korchowiec J, Badis M, Mironiuk-Puchalska E, Fokt I, Priebe W, Rogalska E. Complexation of metal ions in Langmuir films formed with two amphiphilic dioxadithia crown ethers. J Phys Chem B 112(35):10953-63, 2008. e-Pub 2008. PMID: 18698707.
- Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14(18):5759-68, 2008. PMID: 18794085.
- Bednarek E, Sitkowski J, Kawecki R, Kozerski L, Bocian W, Pazderski L, Priebe W. Structure and dynamics of methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-l-lyxo-hexopyranoside complexes with PtCl(2) and PdCl(2), by (1)H, (2)H, (13)C, (15)N and (195)Pt NMR spectroscopy in DMSO, CD(3)CN and H(2)O. Dalton Trans N/A(31):4129-37, 2008. e-Pub 2008. PMID: 18688431.
- Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14(3):788-796, 2008. PMID: 18245540.
- Gruber BM, Anuszewska EL, Bubko I, Kasprzycka-Guttman T, Misiewicz I, Skupinska K, Fokt I, Priebe W. NF kappa B activation and drug sensitivity in human neoplastic cells treated with anthracyclines. Acta Poloniae Pharmaceutica 65(2):267-71, 2008. PMID: 18666436.
- Tamura A, Onishi Y, An R, Koshiba S, Wakabayashi K, Hoshijima K, Priebe W, Yoshida T, Kometani S, Matsubara T, Mikuriya K, Ishikawa T. In Vitro Evaluation of Photosensitivity Risk related to Genetic Polymorphisms of Human ABC Transporter ABCG2 and Inhibition by Drugs. Drug Metab Pharmacokinet 22(6):428-440, 2007. PMID: 18159130.
- Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67(23):11291-9, 2007. PMID: 18056455.
- Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol 60(5):625-33, 2007. e-Pub 2006. PMID: 17195067.
- Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67(20):9630-6, 2007. PMID: 17942891.
- Bidwell GL, Davis AN, Fokt I, Priebe W, Raucher D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest New Drugs 25(4):313-26, 2007. e-Pub 2007. PMID: 17483874.
- Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Fokt I, Priebe W. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz) 55(3):193-8, 2007. e-Pub 2007. PMID: 17557149.
- Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z, Priebe W, Wu J, Donato NJ. Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 109(8):3470-3478, 2007. e-Pub 2007. PMID: 17202319.
- Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs 25(2):115-122, 2007. e-Pub 2006. PMID: 17072745.
- Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26(17):2435-2444, 2007. e-Pub 2006. PMID: 17043651.
- Mansilla S, Rojas M, Bataller M, Priebe W, Portugal J. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem Pharmacol 73(7):934-42, 2007. e-Pub 2006. PMID: 17217917.
- Bidwell GL, Fokt I, Priebe W, Raucher D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem Pharmacol 73(5):620-31, 2007. e-Pub 2006. PMID: 17161827.
- Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684-694, 2007. PMID: 17234779.
- Lampidis TJ, Kurtoglu M, Maher JC, Liu H, Krishan A, Sheft V, Szymanski S, Fokt I, Rudnicki WR, Ginalski K, Lesyng B, Priebe W. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells". Cancer Chemother Pharmacol 58(6):725-34, 2006. e-Pub 2006. PMID: 16555088.
- Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumor cells that contain functional p53. Eur J Pharmacol 540(1-3):34-45, 2006. e-Pub 2006. PMID: 16735036.
- Mansilla S, Priebe W, Portugal J. Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms. Cell Cycle 5(1):53-60, 2006. e-Pub 2006. PMID: 16319532.
- Faderl S, Ferrajoli A, Harris D, Van Q, Priebe W, Estrov Z. WP-1034, a novel JAK-STAT inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML). Anticancer Res 25(3B):1841-50, 2005. PMID: 16158916.
- Gruber BM, Anuszewska EL, Bubko I, Gozdzik A, Priebe W, Fokt I. Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells. Anticancer Res 25(3B):2193-8, 2005. PMID: 16158963.
- Fokt I, Grynkiewicz G, Skibicki P, Przewloka T, Priebe W. New Strategies Towards Synthesis of Doxorubicin Analogs. Polish J. Chem 79:349-359, 2005.
- Frelek J, Kaminska A, Pakulski Z, Szmigielski R, Priebe W. Chirality Probing of Chlorotetrabutyratodiruthenium (II,III) Complexes with vic-Amino Alcohols by Circular Dichroism Spectroscopy. Polish J. Chem 79:387-399, 2005.
- Fox KR, Webster R, Phelps RJ, Fokt I, Priebe W. Sequence selective binding of bis-daunorubicin WP631 to DNA. Eur J Biochem 271(17):3556-66, 2004. PMID: 15317591.
- Mansilla S, Priebe W, Portugal J. Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Biochemistry 43(23):7584-92, 2004. PMID: 15182200.
- Pozarowski P, Huang X, Gong RW, Priebe W, Darzynkiewicz Z. Simple, semiautomatic assay of cytostatic and cytotoxic effects of antitumor drugs by laser scanning cytometry: effects of the bis-intercalator WP631 on growth and cell cycle of T-24 cells. Cytometry A 57(2):113-9, 2004. PMID: 14750133.
- Gruber BM, Anuszewska EL, Priebe W. The effect of new anthracycline derivatives on the induction of apoptotic processes in human neoplastic cells. Folia Histochem Cytobiol 42(2):127-30, 2004. PMID: 15253137.
- Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64(1):31-4, 2004. PMID: 14729604.
- Samochocka K, Fokt I, Anulewicz-Ostrowska R, Przewloka T, Mazurek AP, Fuks L, Lewandowski W, Kozerski L, Bocian W, Bednarek E, Lewandowska H, Sitkowski J Priebe W. Platinum(II) and Palladium(II) Complexes with Methyl 3,4-diamino-2,3,4,6 tetradeoxy-a-L-lyxo-hexopyranoside. Dalton Trans:2177-83, 2003.
- Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21(6A):3777-84, 2001. PMID: 11911247.
- Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 40(18):5542-7, 2001. PMID: 11331019.
Invited Articles
- Priebe, W. Anthracycline Chemistry and Biology 1: Biological Occurrence and Biosynthesis, Synthesis and Chemistry. Journal of the American Chemical Society 131(23):8335, 2009.
Other Articles
- Lin YH, Santani N, Hammoudi N, Ackroyd J, Khadka S, Yan V, Georgiou D, Sun Y, Zielinski R, Tran T, Pando S, Wang X, Maxwell D, Peng Z, Pisaneschi F, Mandal P, Leonard P, Xu Q, Wu Q, Jiang Y, Czako B, Kang Z, Asara J, Priebe W, Bornmann W, Marszalek J, DePinho R, Muller F Eradication of ENO1-deleted Glioblastoma through Collateral Lethality. bioRxiv, 2018.
Abstracts
- Priebe W, Fokt I, Cybulski M, Conrad C, Madden T,Zielinski R, Rusin A. Latentiation of 2-Deoxy-D-glucose. European Journal of Cancer, Proceedings: 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Munich, Germany; Nov 29- Dec 2, 2016 68(Supplement 1), 2016. e-Pub 2016.
- Zielinski R,Fokt I, Rusin A, Skora S, Priebe W. 2-Deoxy-2-halo-D-glucose derivatives inhibition of glycolysis in pancreatic cancer. Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA (#50) 76(14 Supplement). e-Pub 2016.
- Fokt I, Cybulski M, Skora S, Priebe W. Synthesis of selectively acetylated 2-deoxy-D-glucoses, potential agents for treatment. Proceedings: 28th International Carbohydrate Symposium (ICS), New Orleans, LA, July 17-21, 2016 (#46). e-Pub 2016.
- Priebe W. Targeting Pancreatic Cancer. Contemporary Oncology. Proceedings: 8th International Conference of Contemporary Oncology, Poznan, 16-18 March, 2016 19(Supplement 1), 2016.
Book Chapters
- Perez-Soler, R., Khokhar, A.R., Priebe, W., Krakoff, I.H.. Liposomes in Drug Delivery. In: Use of liposomes as carriers of lipophilic antitumor agents. 1st. Routledge: London, 1-9, 2017.
- Debinski W, Priebe W, Tatter S. Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy. In: Glioblastoma. Part I: Targeted Cytotoxic Therapy. Codon Publications: Brisbane (Au), 2014.
Grant & Contract Support
| Title: | Transcriptional and Metabolic Control of Cancer; Design and synthesis of small molecule inhibitors of proliferative and survival pathways |
| Funding Source: | Moleculin LLC |
| Role: | Principal Investigator |
| Title: | Brain SPORE. Project 4. Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway |
| Funding Source: | NIH/NCI |
| Role: | Co-Leader |
| Title: | High-grade Astrocytoma-specific Molecular Targeting |
| Funding Source: | Wake Forest University Health Sciences |
| Role: | Co-Investigator |
| Title: | Maximizing Local Access to Therapeutic Deliveries in Glioblastoma |
| Funding Source: | Wake Forest University Helath Sciences |
| Role: | Co-Principal Investigator |
| Title: | Highly Innovated Targeted Therapy on Melanoma |
| Funding Source: | Houston Pharmaceuticals |
| Role: | PI of Subcontract |
| Title: | Targeted Radionuclide Therapy of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI of Subcontract |
| Title: | Utilizing a small molecule and nanoparticle formulated STAT3 inhibitor to stop the process of tumorigenesis and tumor-mediated immune suppression in a phase I/II clinical trial with unique correlative biomarkers of potential clinical response |
| Funding Source: | The Ben and Catherine Ivy Foundation |
| Role: | Co-Principal Investigator |
| Title: | Microdevice-enabled High Throughput Intratumoral Drug Testing For Ewing Sarcoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Partnership on Central Nervous System Malignancies |
| Funding Source: | University of Bergen |
| Role: | Co-Investigator |
| Title: | Pro-Drug Enolase Inhibitors in Precision Oncology |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Novel Targeted Therapeutics for Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Discovery and Development of Novel Anticancer Agents Targeting CNS malignancies |
| Funding Source: | CNS Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Broad Antiviral Countermeasures against pathogenic RNA viruses |
| Funding Source: | University of Texas Medical Branch |
| Role: | Co-Principal Investigator |
| Title: | Design and synthesis of small molecule inhibitors of proliferative and survival pathways project extension |
| Funding Source: | Moleculin, LLC |
| Role: | Principal Investigator |
| Title: | Targeting Novel Mediators of Breast Cancer Brain Metastasis |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |